Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 31, 2017 - Issue 24
263
Views
8
CrossRef citations to date
0
Altmetric
Short Communication

In vitro growth inhibition and cytotoxicity of Euphorbia caducifolia against four human cancer cell lines and its phytochemical characterisation

, , , , , & show all
Pages 2936-2940 | Received 07 Nov 2016, Accepted 02 Mar 2017, Published online: 13 Apr 2017
 

Abstract

Several Euphorbia species have been used in folklore as cancer remedies, however, scientific studies on the cytotoxicity (in vitro studies) of Euphorbia caducifolia are lacking. In present study, anticancer potential of E. caducifolia aerial parts ethanol extract and its fractions were evaluated against human lung (NCI-H460), breast (MCF-7), prostate (PC-3) and cervical (HeLa) cancer cell lines, using sulphorhodamine-B in vitro cytotoxicity (in vitro studies) assay. The ethanol extract demonstrated growth inhibitory effect against all aforementioned cancer cell lines with IC50, 19–135 μg/mL and LC50, ~220 μg/mL, and its petroleum ether fraction obtained on bioactivity guided fraction showed highest activity with IC50, 28–70 μg/mL and LC50, 71 μg/mL against NCI-H460 and MCF-7 cell lines. Its phytochemicals were analysed by gas chromatography–mass spectrometry (GC-MS). The present study provides scientific justification for its traditional use against cancer.

Acknowledgments

We are grateful to the National Cancer Institute, Frederick, MD, for providing the cell lines under a Material Transfer Agreement.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.